Key points from article :
Kizoo Technology Capital Group led the Series Seed II round for Underdog Pharmaceuticals.
Underdog aims for the first true disease-modifying treatments for age-related conditions.
Custom-engineered cyclodextrins tackle cholesterol derivatives such as 7-ketocholesterol.
Awarded the Innovation Passport under the United Kingdom’s Innovative Licensing and Access Pathway (ILAP).
This will enable faster patient access to its ground-breaking treatment for the prevention of heart attacks and stroke.
The company expects to begin clinical trials in 2023.
Kizoo believes that this industry that will eventually outgrow today’s largest technology markets.
Mike Kope, Underdog Co-CEO, said: “The ILAP award together with the new funds will enable us to further advance to deliver a simple and affordable preventive therapy for the world.”
